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Abstract Purpose: To compare
daily sedation interruption plus pro-
tocolized sedation (DSI ? PS) to
protocolized sedation only (PS) in
critically ill children. Methods: In
this multicenter randomized con-
trolled trial in three pediatric
intensive care units in the Nether-
lands, mechanically ventilated
critically ill children with need for
sedative drugs were included. They
were randomly assigned to either
DSI ? PS or PS only. Children in
both study arms received sedation
adjusted on the basis of validated
sedation scores. Provided a safety
screen was passed, children in the
DSI ? PS group received daily
blinded infusions of saline; children
in the PS group received blinded
infusions of the previous sedatives/
analgesics. If a patient’s sedation
score indicated distress, the blinded
infusions were discontinued, a bolus
dose of midazolam was given and the
‘open’ infusions were resumed:
DSI ? PS at half of infusion rate, PS
at previous infusion rate. The primary
endpoint was the number of ventila-
tor-free days at day 28. Data were
analyzed by intention to treat. Re-
sults: From October 2009 to August
2014, 129 children were randomly
assigned to DSI ? PS (n = 66) or PS
(n = 63). The study was terminated
prematurely due to slow recruitment
rates. Median number of ventilator-
free days did not differ: DSI ? PS
24.0 days (IQR 21.6–25.8) versus PS
24.0 days (IQR 20.6–26.0); median
difference 0.02 days (95 % CI -0.91
to 1.09), p = 0.90. Median ICU and
hospital length of stay were similar in
both groups: DSI ? PS 6.9 days
(IQR 5.2–11.0) versus PS 7.4 days
(IQR 5.3–12.8), p = 0.47, and
DSI ? PS 13.3 days (IQR 8.6–26.7)
versus PS 15.7 days (IQR 9.3–33.2),
p = 0.19, respectively. Mortality at
30 days was higher in the DSI ? PS
group than in the PS group (6/66
versus 0/63, p = 0.03), though no
causal relationship to the intervention
could be established. Median cumu-
lative midazolam dose did not differ:
DSI ? PS 14.1 mg/kg (IQR
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7.6–22.6) versus PS 17.0 mg/kg (IQR
8.2–39.8), p = 0.11. Conclusion: In
critically ill children, daily sedation
interruption in addition to protocol-
ized sedation did not improve clinical
outcome and was associated with
increased mortality compared with
protocolized sedation only.
Keywords Pediatrics 
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Introduction
Commonly, mechanically ventilated critically ill children
are sedated to enhance their comfort and safety. More-
over, a state of sedation facilitates synchronization with
mechanical ventilation and enables invasive procedures to
be performed.
Although sedation is helpful in the care of critically ill
children, it has numerous negative effects. Especially,
oversedation should be avoided, as it is associated with
longer duration of ventilation, longer hospital stay and
adverse patient outcomes, such as withdrawal, delirium
and long-term psychological morbidity in adults [1–4]. In
recent years, efforts have been made to improve sedation
management in children, for example with the use of
sedation algorithms and protocols [5–7]. Nonetheless,
optimal sedation remains challenging and oversedation is
common in pediatric intensive care [8].
In adults, daily sedation interruption (DSI) was
found to be an effective method of improving sedation
management. Clinical trials have shown that DSI can
reduce the duration of mechanical ventilation, hospital
stay and amount of sedatives administered, without
compromising patient comfort or safety [9]. Several
later studies have confirmed this beneficial effect [10],
whereas other studies, in different settings, found no
benefit [11, 12].
For critically ill children, it is unknown if DSI will
improve outcome. Two studies showed that DSI in chil-
dren is feasible, but these studies were not sufficiently
powered to detect differences in clinical outcomes [13,
14]. In a recent study from India comparing DSI with
continuous sedation in children, DSI led to improved
clinical outcomes, including shorter durations of
mechanical ventilation and ICU stay [15]. However,
given the differences in patient population and ICU
practices between the Indian and the Western setting,
these results need further verification [16]. Furthermore, it
is unknown if the combined use of DSI and protocolized
sedation is beneficial in children, as this appears not to be
the case in adults [11]. We hypothesized that mechani-
cally ventilated children managed with DSI combined
with protocolized sedation have more ventilator-free days
at day 28 than patients managed with protocolized seda-
tion alone.
Methods
Patients
We recruited patients from three tertiary medical-surgical
PICUs in The Netherlands: Erasmus MC-Sophia Chil-
dren’s Hospital, Radboud University Nijmegen Medical
Center and Academic Medical Center Amsterdam.
Approval from each institutional review board and written
informed consent from parents or legal representatives
was obtained. The trial has been registered in the Dutch
Trial Register (http://www.trialregister.nl/trialreg/
index.asp), no. NTR2030.
Eligible patients were children between 0 and 18 years
of age, and at least 37 weeks of postconceptual age,
requiring mechanical ventilation with an expected dura-
tion of at least 48 h and need for sedative drugs.
Exclusion criteria were: anticipated death or withdrawal
of life support within 48 h; impossibility of assessing
level of sedation due to an underlying neurologic condi-
tion; neurological, respiratory or cardiac instability that
may not tolerate inadequate sedation; therapeutic
hypothermia after cardiopulmonary resuscitation; difficult
airway; fixed duration of mechanical ventilation (e.g.,
until planned operation); admission for ECMO; already
having been ventilated/sedated for[2 days in a trans-
ferring PICU; and no informed consent.
Study design
The study design of this randomized controlled trial has
previously been described in detail [17]. In short, within 24 h
after intubation, informed consent was obtained and, the
morning after enrollment, the patient was assigned to either
DSI combined with protocolized sedation (DSI ? PS group)
or protocolized sedation only (PS group).
Randomization and blinding
Patients were randomly assigned in a 1:1 ratio to either
DSI ? PS or PS, using blocked randomization with
stratification by center and age group (0–30 days,
30 days–2 years, and 2–18 years). An independent
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biostatistician carried out computer randomization in
advance.
In both groups, the syringes containing sedatives/
analgesics were replaced each morning with blinded
syringes, provided a safety screen was passed. The
pharmacist had access to group allocation to be able to
prepare blinded infusions. In the DSI ? PS group, the
infusions were replaced with saline infusions, in the PS
group, the infusions were replaced with blinded infusions
containing the same sedative and analgesic drug con-
centrations. In this way, the caregiving nurse was blinded
for group allocation, so as to minimize bias in assessing
the sedation level. If a patient’s sedation score indicated
distress, the blinded infusions were discontinued, a bolus
dose midazolam was given and the original ‘open’ infu-
sions were restarted at 50 % of the rate for the DSI ? PS
a Sedation protocol, basic scheme 
Sedation protocol
basic scheme
COMFORT score each 8 hrs
(2-10-18 hr) and/or at distress/
increased restlessness
CF
11-22 and
NISS=2
CF 6-10 or
CF 11-22
and NISS=3
CF 23-30
CF
11-22 and
NISS=1
1. Melatonine (oral)
2.5 mg <1 yrs, 5 mg >1 yrs
2. Lorazepam (oral)
0.05 mg/kg
Repeat COMFORT score
after 1 hour
CF 11-22
and NISS=2
Nursing interventions and
medical therapy applied to
satisfaction
Follow weaning scheme:
- Midazolam
- Midazolam + Morphine
- Midazolam >5 days
(go to page 6)
No
intervention
Restlessness/ distress
because of difficulty
falling asleep
Consider other
strategies
NoYes
Coming from pages 3-8
CF = COMFORT behavior score
NISS = Nurse Interpretation of Sedation Score
Follow sedation algorithm
ventilated patient
Fig. 1 Sedation protocol
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group and at the original rate for the PS group. This
infusion rate was visible for the caregiving medical team.
For restart of the ‘open’ infusions, the bedside nurse
opened an envelope placed in the study binder at the
patient’s bedside to identify group allocation. The
envelope was then closed again and returned to the study
binder. This procedure was repeated on every study day.
Effectively, only the first start of the blinded infusions
resulted in a complete blinding of treatment for the
medical team. After the first restart, they could be aware
of the patient’s allocation, if they deduced that the full or
50 % resumption of the infusion rate the day before
indicated group assignment. For safety reasons, complete
blinding was deemed not to be feasible.
b Sedation protocol, increasing decision tree 
Algorithm sedation of ventiltated patient 
Medical therapy to be performed by
nurses independently.
NOTE:
Do not perform in neonates with
gestational age < 37 weeks,
traumatic brain injury, 
status epilepticus,
Reduce distress by nursing
interventions.
Midazolam* (iv):
0.1 mg/kg bolus +
100 mcg/kg/h infusion
Repeat COMFORT score
after 30 min.
CF 11-22
and NISS=2
Midazolam* (iv):
Increase to max. 300 mcg/kg/h
in steps of 100 mcg/kg/h
+ bolus 0.1 mg/kg per
step (= 30 min.)
Add Morphine (iv):
100 mcg/kg bolus +
10 mcg/kg/u infusion
Repeat COMFORT score
after 30 min.
CF 11-22
and NISS=2
Morphine (iv):
Increase to max. 30 mcg/kg/h
in steps of 10 mcg/kg/h
+ bolus of 50 mcg/kg per
step (= 30 min.)
COMFORT score each 8 hrs
(2-10-18 hr) and/or  at
distress/increased restlessness
To page 2
"interventions
to satisfaction"
Consider other medication (physician's responsibility):
- Ketamine (iv): 0.5 mg/kg bolus; 0.5 mg/kg/h infusion.
- Clonidine (iv): 2 mcg/kg bolus; 0.2-2 mcg/kg/u infusion of oral: 1-5 mcg/kg a time
3-4 dd.
- Propofol (iv): 1 mg/kg bolus; 1 mg/kg/h infusion (note: not in children below 12
years of age, for long-term infusion).
- Fentanyl (iv): 1-2 mcg/kg bolus; 1-3 mcg/kg/h infusion (instead of morphine).
- Long-term infusion (>7days) of midazolam, consider switching tolorazepam
(stable and/or long term ventilation).
- Alimemazine, 1mg/kg (oral)
* Evaluation of hemodynamics is essential after
start midazolam
Yes
Yes
No
No
No, and midazolam max (300 mcg/kg/h)
No
Fig. 1 continued
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Protocolized sedation
All study centers used a standardized sedation protocol
for adjustment of sedatives and analgesics, based on
scores on validated instruments for this population
[COMFORT behavior scale (COMFORT-B), nurse
interpretation of sedation score (NISS), numeric rating
scale (NRS)] [18, 19]. All nurses had been trained to use
these instruments. Inter-observer variability was satis-
factory, with j[ 0.65 for all nurses. Adequate sedation
was defined as a COMFORT-B score C11 and B22.
A COMFORT-B score of\11 implied oversedation, a
score [22 implied undersedation. Upon a patient’s
admission to the PICU, the need of sedation was assessed.
If sedation was needed, midazolam was initiated and
titrated up to a maximum of 300 lg/kg/h. When sedation
was still considered insufficient, morphine (up to 30 lg/
kg/h) was added to the midazolam treatment. If a patient
remained distressed and sedation still seemed inadequate,
other sedative drugs were added according to local stan-
dard practice (see Fig. 1a, b).
Intervention group (DSI ? PS)
After having been on mechanical ventilation for 24 h, a
patient was assessed for a safety screen daily at 1000 h,
after routine care. A patient passed the screen unless he/
Fig. 2 Flowchart of study design
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she received a sedative infusion for active seizures,
escalating sedative doses due to ongoing agitation, neu-
romuscular blockers, had evidence of increased
intracranial pressure or in cases of cardiorespiratory
instability as judged by the bedside clinician. Patients
who did not pass the screen were reassessed after 24 h. If
the patient passed the screen, all sedative and opioid
infusions were replaced with blinded infusions containing
saline. Analgesics needed for active pain were continued
(e.g., pleural drain,\24 h after surgery). During blinded
infusions, the patient was strictly monitored and comfort
was assessed at least every 2 h using the COMFORT-B
and NRS scores or earlier if distress was apparent. The
sedative and opioid infusions were restarted if the patient
appeared uncomfortable or if this was deemed necessary
in view of cardiorespiratory instability. After a loading
dose of midazolam (0.1 mg/kg, intravenously), sedative
infusions were restarted at half the previous dose and then
titrated according to the sedation protocol to achieve
adequate sedation (Fig. 2).
Control group (PS)
In the control patients, following the safety screen, blin-
ded infusions were started at the same infusion rate as the
patient was receiving, containing the same medication,
effectively continuing the sedation. Level of sedation was
assessed in the same way as in the DSI ? PS group.
When assessments indicated distress, a loading dose of
midazolam was given, and the blinded infusions were
replaced with the sedative infusions at a similar rate as
before the start of blinded infusions and subsequently
titrated according to the sedation protocol to achieve
adequate sedation.
Endpoints
The primary endpoint was the number of ventilator-free
days at day 28, defined as the number of days a patient
had breathed without mechanical ventilation for at least
1059 patients assessed for eligibilty
132 randomly assigned to treatment
Erasmus MC n=94
Radboud n=22
AMC n=16
927 excluded
646 for clinical reasons
322 needed sedatives
47 status epilepticus
56 hypothermia after CPR
53 traumatic brain injury
74 congenital diaphragmatic hernia
34 respiratory instability
58 cardiac instability
28 anticipated death <48 h
52 neurological deficits
76 required ECMO
43 difficult airway
30 premature
56 fixed duration of MV
39 had been ventilated > 2 days
281 for other reasons
159 refused to participate
62 logistic reasons
32 enrolled in another trial
28 other
67 assigned to daily sedation interruption 65 assigned to protocolized sedation
66 analysed 63 analysed
1 excluded 
<48 h ventilation
2 excluded 
1 <48 h ventilaion
1 withdrawal informed 
consent
Fig. 3 Flowchart of recruited patients
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48 h continuously during a 28-day period after random-
ization. Patients who died during this 28-day period were
assigned zero ventilator-free days.
Secondary outcomes included: length of stay in the
ICU and hospital (days); 30-day mortality; total and
median dose of midazolam and morphine (mg/kg);
number of COMFORT-B scores \11 and [22; use of
additional sedative drugs during ventilation; incidence of
withdrawal symptoms [Sophia Observation withdrawal
Symptoms (SOS) scale [20]]; adverse events; total num-
ber of safety screen assessments; and number and reason
for failure to pass.
Statistical analysis
The Erasmus MC institutional admission data for the year
2008 showed that 168 children were mechanically ven-
tilated for at least 48 h in our PICU with a mean number
of 16.5 (SD 9.9) ventilator-free days. On this basis,
including 100 patients per group would be sufficient to
detect a clinically significant difference of 25 % in ven-
tilator-free days (i.e. mean 20.6 days in the DSI ? PS
group vs. 16.5 days in the PS group), with a power of
80 %, based on a Mann–Whitney test with a significance
level of 5 %.
Table 1 Baseline characteristics
DSI ? PS (n = 66) PS (n = 63)
Age (months) 2.8 (1.1–17.1) 2.7 (1.3–14.0)
0–30 days (group A) 12 (18.2 %) 11 (17.5 %)
30 days–2 years (group B) 40 (60.6 %) 38 (60.3 %)
2–18 years (group C) 14 (21.2 %) 14 (22.2 %)
Gender (male/female) 38/28 (57.6/42.4 %) 41/22 (65.1/34.9 %)
Weight (kg) 5.0 (3.7–10.0) 4.6 (3.7–11.0)
PRISM II 16.5 (13–24) 16 (11–21)
Predicted mortality PIM 2 (%) 4.3 (1.6–10.0) 3.2 (1.5–7.6)
PELOD 11 (8–20) 11 (11–20)
Diagnosis on admission
Respiratory disordera 47 (71.2 %) 40 (63.5 %)
Cardiac disorderb 3 (4.5 %) 4 (6.3 %)
Sepsis 7 (10.6 %) 6 (9.5 %)
Surgery
Cardiac 7 (10.6 %) 7 (11.1 %)
Non-cardiac 1 (1.5 %) 2 (3.2 %)
Other 1 (1.5 %) 4 (6.3 %)
Sedation before randomization (mg/kg)c
Midazolam 3.6 (2.4–5.7) 3.1 (2.4–5.2)
Morphine 0.25 (0.12–0.43) 0.35 (0.14–0.46)
Data are in median (IQR) or n (%)
PRISM II pediatric risk of mortality, PIM 2 pediatric index of
mortality, PELOD pediatric logistic organ dysfunction
a Viral/bacterial pneumonia, ARDS and asthma
b Congenital heart disease and cardiomyopathy
c Cumulative dose (infusion and bolus) in the first 24 h after
intubation
Table 2 Main study outcomes
DSI ? PS (n = 66) PS (n = 63) p value
Ventilator free days at 28 days (days) 24.0 (21.6–25.8) 24.0 (20.6–26.0) 0.90
Duration of mechanical ventilation (days) 5.1 (3.7–7.3) 5.2 (3.6–9.0) 0.71
Reintubation\24 h 2 (3.0 %) 9 (14.3 %) 0.03
Tracheostomy 1 (1.5 %) 1 (1.6 %) 1.00
Length of stay ICU (days) 6.9 (5.2–11.0) 7.4 (5.3–12.8) 0.47
Length of stay hospital (days) 13.3 (8.6–26.7) 15.7 (9.3–33.2) 0.19
30-day mortality 6 (9.1 %) 0 (0 %) 0.03
Adverse events
Self-extubations 1 4 0.20
Of which requiring reintubation 0 2 0.24
Oversedation–flumazenil 0 1 0.49
Fixation (need for soft wrist restrainers) 1 0 1.00
Data are in median (IQR) or n (%)
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Data were analyzed blinded, with an intention-to-treat
approach. Descriptive data are presented as percentage,
mean ± SD for normally distributed variables, and
median ± IQR for non-normally distributed variables.
Distribution of categorical variables between groups was
compared with Fisher’s exact tests; continuous variables
with Mann–Whitney tests. The primary outcome was also
compared between groups with correction for baseline
variables [age, sex, pediatric logistic organ dysfunction
(PELOD) score and type of disease], using robust multi-
ple linear regression analysis to account for the non-
normal distribution of the model residuals. Effects of
treatment on length of stay in the ICU and hospital were
assessed with time-to-event analysis, i.e. Kaplan–Meier
analysis and log-rank test. These tests also served to
assess the effect on 30-day mortality. Penalized Cox
analysis was used to assess differences between the
groups after adjustment for the baseline variables men-
tioned above. All statistical tests were two-tailed and the
significance level was set at 0.05. Statistical analyses were
performed using SPSS (v.21) and R (v.3.1.2) for robust
regression analysis.
An interim analysis was not scheduled, but an inde-
pendent data and safety monitoring board (DSMB)
continuously evaluated possible adverse events.
Results
Participants
Of 1059 eligible patients, 132 patients were included in
the study between October 2009 and August 2014.
Table 3 Sedation profiles
DSI ? PS (n = 66) PS (n = 63) p value
Midazolam n = 66 n = 63
Cumulative dose infusion (mg/kg) 13.0 (6.9–22.3) 17.0 (8.1–39.8) 0.08
Mean infusion rate (lg/kg/h) 126 (59–185) 134 (90–221) 0.02
Cumulative dose bolus (mg/kg) 0.74 (0.24–1.21) 0.52 (0.20–1.19) 0.21
Total cumulative dose (mg/kg) 14.1 (7.6–22.6) 17.0 (8.2–39.8) 0.11
Number of exposure days 4.5 (3.4–6.7) 4.9 (2.8–8.7) 0.79
Morphine n = 54 n = 52
Cumulative dose infusion (mg/kg) 0.89 (0.5–1.4) 1.15 (0.6–2.8) 0.12
Mean infusion rate (lg/kg/h) 9.7 (6.3–13.0) 11.9 (10.0–16.4) 0.004
Cumulative dose bolus (mg/kg) 0.15 (0.06–0.36) 0.10 (0.02–0.14) 0.03
Total cumulative dose (mg/kg) 0.92 (0.60–1.56) 1.16 (0.65–2.86) 0.17
Clonidine n = 13 n = 11
Cumulative dose infusion (lg/kg) 55.2 (15.8–95.1) 92.6 (43.2–208.3) 0.04
Mean infusion rate (lg/kg/h) 0.56 (0.42–0.92) 0.98 (0.66–1.52) 0.01
Cumulative dose bolus (lg/kg) 4.08 (2.24–4.73) 6.43 (3.04–10.50) 0.15
Total cumulative dose (lg/kg) 47.4 (8.0–86.7) 75.7 (41.2–204.8) 0.10
Ketamine n = 9 n = 17
Cumulative dose infusion (mg/kg) 15.3 (6.8–108.0) 35.8 (6.4–94.9) 0.85
Mean infusion rate (mg/kg/h) 0.54 (0.27–1.14) 0.74 (0.30–0.97) 0.83
Cumulative dose bolus (mg/kg) 0.92 (0.50–1.89) 1.09 (0.50–3.48) 0.72
Total cumulative dose (mg/kg) 4.51 (0.52–26.20) 35.63 (3.11–56.17) 0.11
Fentanyl n = 34 n = 28
Cumulative dose (lg/kg) 4.1 (2.1–12.3) 2.3 (1.2–7.9) 0.15
Propofol n = 24 n = 29
Cumulative dose (mg/kg) 6.5 (2.8–26.2) 10.8 (2.6–40.7) 0.57
Number of different sedatives received 2 (2–3) 2 (2–4) 0.31
Number of patients with[2 sedatives 24 (36.4 %) 26 (41.3 %) 0.57
COMFORT-B scale
Total number of assessments 3389 3924
Median number of assessments per patient 41 (28–59) 47 (26–76) 0.45
Median COMFORT-B score 12 (11–15) 12 (10–14) 0.048
Oversedation (COMFORT-B\11), n (%) 824 (24.3 %) 998 (25.4 %) 0.27
Undersedation (COMFORT-B[22), n (%) 107 (3.2 %) 93 (2.4 %) 0.04
SOS score
Number of patients 19 20
Total number of assessments 317 540
Median number of assessments per patient 9 (3–21) 16.5 (9–39) 0.07
Median SOS 1.0 (0.5–2.0) 1.0 (1.0–2.8) 0.23
SOS C4, n (%) 32 (10.1 %) 66 (12.2 %) 0.35
Data are in median (IQR) or n (%)
n the number of patients receiving the drug
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Recruitment rates were lower than foreseen, and the study
was terminated prematurely, before the recruitment of
200 patients. Three patients were excluded from the
analysis because they were on mechanical ventilation for
\48 h or informed consent was withdrawn before the
start of the study (Fig. 3). Consequently, 129 children
were analyzed, 66 in the DSI ? PS group and 63 in the
PS group.
Eight patients (12 %) in the DSI ? PS group discon-
tinued the protocol. Three of those were placed on
ECMO, two were withdrawn by the medical team (one
because of clinical instability and one because deeper
sedation was thought necessary), two patients were
withdrawn by parents (concerned that their child was
insufficiently sedated), and one patient was transferred to
the neonatology ward. In the PS group, four patients
(6 %) discontinued the protocol. Two of those were
placed on ECMO, one was withdrawn by the medical
team (because of clinical instability), and one was with-
drawn by the parents. Baseline characteristics of the two
groups were similar (Table 1). Most patients (67 %) were
admitted for a non-surgical condition such as respiratory
disorders.
Main outcomes
Table 2 shows that the median number of ventilator-free
days was 24.0 days in both groups [median difference
0.02 (95 % CI -0.91 to 1.09), p = 0.90]. Adjustment for
baseline variables gave similar results [mean difference
0.04 (95 % CI -1.04 to 1.11), p = 0.95]. In the PS group,
more re-intubations were needed (9 vs. 2, p = 0.03). The
number of accidental extubations was not different
between groups (DSI ? PS group n = 1/66, PS group
n = 4/63, p = 0.20). ICU and hospital length of stay did
not differ significantly between the groups (Table 2).
Mortality at 30 days was significantly higher in the
DSI ? PS group [6 (9.1 %) vs. 0 (0 %), p = 0.02 using
log-rank test], also after adjustment for baseline variables.
The DSMB reviewed the causes of mortality and could
not determine a causal relation between intervention and
outcome for these six deaths in the DSI ? PS group. The
intervals between last blinded infusion and death were 1,
7, 20, 23 and 27 days, while one patient did not receive
blinded infusion at all. Three of these six patients were
withdrawn prematurely from the study because of the start
of ECMO. Two others died from ongoing sepsis with
progressive deterioration and multiple organ failure, and
one patient suffered from a pneumonia in aplasia with
critical illness neuropathy.
Sedative medication
Sedation profiles are presented in Table 3. As a reflection
of the protocol, mean infusion rates were lower in patients
treated with DSI ? PS. However, cumulative dose was
not different between the groups, as patients treated with
DSI ? PS received more boluses of midazolam [median
cumulative midazolam dose (infusion ? boluses)
14.1 mg/kg (IQR 7.6–22.6) vs. 17.0 mg/kg (IQR
8.2–39.8), p = 0.11]. Also, for the other sedative drugs,
no significant difference was found in cumulative dose.
Median number of days of exposure to midazolam and
number of agents received were not different. The median
duration of blinded infusions was 25.9 h (IQR
10.1–48.8 h) in the DSI ? PS group versus 41.4 h (IQR
Table 4 Safety screen
DSI ? PS (n = 66) PS (n = 63)
Median number of assessments per patient 4 (3–5) 4 (3–6)
Total number of assessments 302 354
Pass 198 (65.6 %) 261 (73.7 %)
Fail 69 (22.8 %) 76 (21.5 %)
No sedation 35 (11.6 %) 17 (4.8 %)
Reason for failure
Active seizures 0 (0 %) 3 (3.9 %)
Ongoing agitation 24 (34.8 %) 33 (43.4 %)
Neuromuscular blockade 7 (10.1 %) 24 (31.6 %)
Increased ICP 0 (0 %) 0 (0 %)
Cardiorespiratory instability 38 (55.1 %) 16 (21.1 %)
No. of patients with
0 fail 40 (60.6 %) 40 (63.5 %)
1 fail 10 (15.2 %) 8 (12.7 %)
2 fail 6 (9.1 %) 8 (12.7 %)
3 fail 3 (4.5 %) 1 (1.6 %)
4 fail 3 (4.5 %) 2 (3.2 %)
5 fail 3 (4.5 %) 2 (3.2 %)
[5 fail 1 (1.5 %) 2 (3.2 %)
Data are in median (IQR) or n (%)
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23.8–75.7 h) in the PS group, p = 0.003. In nine patients
in the DSI ? PS group, there was no need to restart
sedation after the first interruption. These patients were
comfortable without sedation for a median of 48.5 h
(range 23.5–74.5 h) until extubation.
Distress assessments
Median COMFORT-B scores were slightly lower in the
PS group than the PS ? DSI group, indicating that they
were more deeply sedated [12 (IQR 10–14) vs. 12 (IQR
11–15), p = 0.048] (Table 3). The median (IQR) number
of assessments per subject was not different between
groups. Univariate analysis revealed that 824 (24.3 %) of
the scores in the DSI ? PS group indicated oversedation
(COMFORT-B\11), versus 998 (25.4 %) of the scores
in the PS group (p = 0.27). Undersedation (COMFORT-
B[22) was more frequent in the DSI ? PS group [3.2 %
(n = 107) vs. 2.4 % (n = 93), p = 0.04].
All patients were oversedated at some point during the
study period, whereas 62 of 129 patients (n = 34 patients
in the DSI ? PS group and 28 in the PS group) were
undersedated at some point.
Median SOS scores were comparable between groups
(Table 3). Total number of SOS assessments was signif-
icantly higher in the PS group (540 vs. 317 scores,
p = 0.001). In total, 25 patients had a SOS score of C4
during the study period (n = 10 in the DSI ? PS group,
n = 15 in the PS group, not significant), indicating
withdrawal symptoms.
Safety screen
Two-thirds of all safety screens were passed, 198
(65.6 %) of 302 in the DSI ? PS group and 261 (73.7 %)
of 354 in the PS group. Agitation and cardiorespiratory
instability were the main reasons for failing the safety
screen (Table 4). Approximately 60 % of the patients
passed all safety screens performed (60.6 % in the
DSI ? PS group and 63.5 % in the PS group).
Discussion
This multicenter randomized controlled trial showed no
difference in ventilator-free days and ICU or hospital length
of stay for children treated with daily interruption of sedation
combined with protocolized sedation compared with chil-
dren receiving protocolized sedation alone. Additionally,
DSI ? PS was not associated with the administration of less
sedative drugs compared with the use of PS.
These findings contradict those of two earlier studies
on DSI in children, in both of which DSI was associated
with shorter durations of mechanical ventilation, shorter
ICU stays and less use of sedatives [13, 15].
This discrepancy can perhaps be explained as follows.
First, we compared DSI in the setting of a protocolized
sedation strategy for all patients, the latter being standard
of care in the participating PICUs. A nurse-driven seda-
tion protocol is assumed to be beneficial to minimize
sedation, although this was recently questioned in a study
in critically ill children [6, 21]. The effect of protocolized
sedation itself on the clinical endpoints might have out-
weighed the effect of DSI. This is in line with an adult
study in which DSI offered no benefit over a nurse-driven
protocol already targeting light sedation [11]. Also, the
previous pediatric pilot study used no sedation protocol
and patients in the control group were deeply sedated
[13], which could explain the beneficial effect of DSI.
Second, there are important differences between the
present study and that of Gupta and colleagues which
could explain the different study outcomes [15]. In the
latter, around 70 % of the patients had neurological ill-
nesses, while we did not include patients with
neurological problems. Moreover, mean duration of
mechanical ventilation was 10.3 days in the continuous
group, versus 5.2 days in our population. Lastly, the daily
dose of midazolam was almost twice that in the present
study (mean 11.0 vs. 6.1 mg/kg/day in the control groups
and mean 7.1 vs. 4.4 mg/kg/day in the DSI groups).
In the present study, cumulative drug doses did not
significantly differ between the two groups. The need for
intermittent bolus administration in the DSI ? PS group
counterbalanced the reduction in continuous sedation.
However, in nine patients in the DSI ? PS group, there
was no need to restart sedation. It seems that there are two
groups of patients: (1) patients who may not need sedation
at all and (2) patients who become agitated after sedation
interruption and even need more (bolus) medication to
become comfortable again. Therefore, a continuous crit-
ical appraisal of the need to continue sedation is
warranted. Active tapering of sedation is still needed as
this may improve outcome, in particular in the first group.
More reintubations were needed in the PS group.
Patients in the DSI ? PS group were possibly more alert
and therefore extubation may have been more successful,
as also demonstrated in adult DSI studies [10]. Overall,
around a quarter of the distress assessments indicated
oversedation. This is somewhat lower than described in
the literature [8], possibly due to the use of a sedation
protocol. Judging from the higher number of SOS
assessments in the PS group, these patients showed more
clinical withdrawal symptoms, although no statistically
significant difference was found in the number of scor-
es C4, sedative drug doses, and length of exposure to
midazolam between the two groups.
This study shows that DSI in children is feasible.
Around 60 % of patients passed all safety screens, and
DSI was not related to more adverse events, in line with
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earlier studies. However, the higher mortality in the first
30 days in the DSI ? PS group (9.1 %) compared to the
control group was totally unexpected, as also was the
absence of mortality in the control group (0 %). Reas-
suringly, overall 30-day mortality in our total patient
cohort (6/129; 4.6 %) was not higher than the reported
ICU mortality in the Netherlands [22]. Moreover, an
independent DSMB could not identify a causal relation-
ship between the study intervention and cause of death for
individual patients. All six patients were seriously ill, with
a high mortality risk in advance. Furthermore, the time-
frame between active participation in the study and death
makes a causal relationship unlikely.
In previously published DSI studies, mortality was
never increased. In adult studies, reported ICU mortality
was 29.8 % in the DSI group and 31 % in the usual care
group (RR 0.96, 0.77–1.21) [23]. Pooled adult data also
demonstrated no difference in overall mortality (RR 0.88,
0.75–1.05) and 28-day mortality (RR 0.82, 0.5–1.12)
between DSI and control groups [23]. In children, Gupta
reported a mortality of 26.1 % in the DSI group and
26.8 % in the control group [15]. Both percentages are
higher than our reported mortality due to a different ICU
setting and different population, but mortality was not
increased in DSI patients. In the pediatric pilot study, all
patients survived until PICU discharge [13]. We could not
establish a theoretical framework explaining the increased
mortality found in our study. Considering all this, and
given that meta-analyses of trials had not previously
identified an adverse mortality risk with DSI, it is highly
unlikely that there is a relationship with DSI. Neverthe-
less, while our finding may be due to a type I error, we
cannot exclude that the increased mortality in our study is
due to an unexpected impact of the study protocol.
A limitation of our study is the smaller-than-planned
sample size. The planned inclusion of 200 patients was not
reached due to slow recruitment rates. The number of eli-
gible patients was lower than expected and around 50 % of
parents declined to provide consent [24]. The reasons for
these refusals were not recorded, but it is not unreasonable
to assume that these parents found the concept of discon-
tinuing drugs given to promote comfort not acceptable, as
also suggested in an adult DSI trial with the same consent
rate [25]. It would probably take another 2.5 years to finish
recruitment of all planned 200 patients. This timeframe was
deemed not feasible by the study group, and at this point it
was decided to stop the study. The decision was not influ-
enced by interim results as data were still blinded at the time
of the decision. Still, we believe our results are valuable. A
post hoc power analysis resulted in a power of 62 % with
129 patients, although the expected mean number of ven-
tilator-free days in the sample size calculation was lower
than observed in the study, likely due to the selection of
relatively more stable patients. Since we did not even find a
trend in the number of ventilator-free days or the length of
stay between both groups, it is unlikely that we would find a
clinically meaningful difference with 200 patients. Fur-
thermore, this study can provide useful data to assist others
who might be planning a trial or performing a meta-anal-
ysis. Another consideration of the study is that, in the
DSI ? PS group, 22.8 % of the safety screens were not
passed, and for that day sedation was not interrupted. This
could have diminished the differences between the two
groups. However, this reflects clinical practice and is
comparable with adult DSI studies [11]. Furthermore, there
may be a Hawthorne effect in the control group [26], as
sedation practice was closely monitored in both groups
possibly leading to a better adherence to the sedation pro-
tocol. A strength of this study is the multicenter design. This
reflects actual practice in different PICUs and enhances the
generalizability of these findings.
Conclusions
Based on this multicenter study, there is no beneficial
effect of daily sedation interruption in addition to proto-
colized sedation for critically ill children. Daily sedation
interruption did not reduce the duration of mechanical
ventilation, the length of stay, or the amounts of sedative
drugs administered, but was associated with a higher
30-day mortality. Therefore, daily sedation interruption is
not the sedation strategy of choice in critically ill children
provided protocolized sedation is implemented in the
pediatric intensive care.
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